Parkinson's patients get early access to experimental drug tavapadon
NCT ID NCT07158827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program allows eligible people with Parkinson's disease to receive tavapadon, an experimental oral tablet, before it is officially approved. A doctor must decide if the potential benefit outweighs the risks. The program is only available in certain territories and for those who cannot join ongoing clinical trials or have no other suitable treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tavapadon (oral tablet)
What this could lead to
If successful, this program could offer early access to a new treatment option for Parkinson's disease before it is officially approved.
What could go wrong
This is an expanded access program, not a clinical trial, so data on safety and effectiveness is limited. Tavapadon is still investigational and may have unknown risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••